BMA eps in a glimpse
Analyst Rating Consensus
1
Ratings
BMA Price Target
Highest Price Target
$12.50
-88.8% Downside
)Mean Price Target
$12.25
-89.03% Downside
)Lowest Price Target
$12.00
-89.25% Downside
)BMA Recent Analyst Ratings
Actual EPS vs Estimated EPS
How EPS can be helpful
Understanding the true essence of Earnings Per Share (EPS) for a company can be a complex endeavor. EPS, essentially a measure of a company's profitability on a per-share basis, is often used by investors as a barometer of financial health. However, it's crucial to recognize that EPS can be subject to manipulation through various accounting techniques and management strategies.
BMA Earnings History
After EPS - Where did the stock go?
Frequently Asked Questions
Brokerage firms have given BMA stock an average recommendation of Strong Buy. 1 analysts have given their ratings to BMA out of which 1 analysts have given strong buy call, 0 analysts have given buy call, 0 analysts rate it hold, 0 analysts advocate strong sell call, and 0 analysts has given sell rating. The average target price of $12.25 gives the stock implied upside of roughly -89.03% over the next year or so.
Analysts suggest BMA's stock price would rise to a high of $12.50.
Within the next 12 months, analysts predict the BMA stock price could move to $12.00.
BMA stock has an average analyst estimate of $12.25.
BMA shares are currently trading -89.03% below this price target.
Its quarterly earnings per share (EPS) came in at $5.17 versus consensus estimates of $2.19, and above the comparable year-ago quarter’s EPS of $1.47.
BMA's forecasts by analysts estimating quarterly EPS at $2.36 and $24.77 for the whole year.
The analysts have projected N/A EPS growth for BMA in the next five years, compared to growth rates of 29.81% in the past five years.